Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Global Nuclear Medicine Market 2016 Share, Trend, Segmentation and Forecast to 2020

Monday, November 7, 2016 3:01
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The Global Nuclear medicine market has been estimated to be valued at USD 11.04 Billion for the year 2015 and the market is expected to hit USD 19.4 billion by the year 2020 at a CAGR of 12.3%. The market is set to be mostly driven by the therapeutic radio pharmaceuticals, which are expected to grow at CAGR of 30% during 2015 to 2020. 

Request a sample report @

Though in existence since the 1940s the nuclear medicine market came to the forefront only in the past decade mostly due to the emergence of new radio nucleotides and the number of products under development has grown since then, at an increasing pace. Nuclear medicine has applications in the fields of cardiology, lymphoma, thyroid, neurology oncology, and others. 
Increasing incidences of cancer and cardiac ailments, Increasing awareness for radiopharmaceuticals, and ready availability of radiopharmaceuticals are the major driving forces for this market. Increased public awareness and use of Radio diagnostic techniques such as SPECT and PET also fuel the market growth. Some of the major constrains for the market are shorter half- life of radioisotopes, high capital investment, regulatory guidelines and reimbursement issues. 
The radiopharmaceutical market is broadly classified into two segments, namely diagnostic and therapeutic. Diagnostic radioisotope segment is sub-divided into SPECT isotopes (Technetium-99m (TC-99m), Thallium-201 (TL-201), Iodine (I-123) and Gallium) and PET radioisotopes (Fluorine-18, Rubidium-82 (RB-82)). Therapeutic radioisotopes segment is divided into Alpha emitters (Radium-223), Beta Emitters (Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (iodine-125, Cesium-131, Palladium-103, & Iridium-192). Diagnostic radioisotopes segment holds the largest share in Nuclear Medicine Radioisotopes Market 
Based on geography, the market is segmented into North America, Europe and Asia-Pacific and Rest of the World. North America is the dominant market for diagnostic radioisotopes. Within North America, USA is the largest consumer market for radioisotopes and Canada is the largest producer of Tc-99m. Germany is the largest consumer market for radiopharmaceuticals in the Europe. India and China hold a potential market for radioisotope due to rising healthcare requirement both diagnostic and therapeutic leading to an increase in demand for different radioisotopes in various treatments and applications 
Many players in this market are trying to expand their product portfolio in order to top the global market. Few companies adopted product innovation and new product launches as its key business strategy to ensure its dominance in this market. Some of the major players in the radiopharmaceuticals market are Covidien Plc (Ireland), GE Healthcare (U.K.), IBA Group (Belgium), Lantheus Medical Imaging, Inc. (U.S.), Nordion Inc. (Canada), and Siemens Healthcare (PETNET) (Germany). 
Key Deliverables in the Study 
1. Market analysis for the Global Nuclear medicine market, with region specific assessments and competition analysis on global and regional scales 
2. Market definition along with the identification of key drivers and restraints 
3. Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale 
4. Extensively researched competitive landscape section with profiles of major companies along with their market shares 
5. Identification and analysis of the macro and micro factors that affect the Global Nuclear medicine market on both global and regional scales 
6. A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information 
7. A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market 
8. Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

Complete report details @       

Key points in table of content

1. Introduction 
    1.1 Study Deliverables 
    1.2 Market Definition 
    1.3 Sizing Units 
    1.4 Base Currency 
    1.5 Review and Forecast Period Years 
    1.6 General Study Assumptions 
2. Research Methodology 
2.1 Introduction 
2.2 Analysis Methodology 
2.3 Econometric Forecast Model 
2.4 Research Assumptions 
3. Executive Summary 
4. Key Inferences 
5. Market Overview and Industry Trends 

5.1 Current Market Scenario 
5.2 Applications of Nuclear Medicine 
5.3 Technology Overview 
5.4 New Developments 
5.5 Investment Analysis 
5.6 Porter’s Five Forces 
5.6.1 Bargaining Power of Suppliers 
5.6.2 Bargaining Power of Consumers 
5.6.3 Threat of New Entrants 
5.6.4 Threat of Substitute Products and Services 
5.6.5 Competitive Rivalry within the Industry 
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) 
    6.1 Market Drivers 
6.1.1 Increasing Incidents of Cancer and Cardiac Ailments 
6.1.2 Increasing SPECT AND PET applications 
6.1.3 Growing Public Awareness for healthcare 
    6.2 Market Restraints 
6.2.1 Short Half-life of Radiopharmaceuticals 
      6.2.2 High Capital Investment 
      6.2.3 Regulatory Guidelines 
      6.2.4 Reimbursement 
    6.3 Key Challenges 
    6.4 Current Opportunities in the Market 
      6.4.1 Increasing Imaging Technologies 
      6.3.2 Potential Radioisotopes in Pipeline 
      6.3.3 Increasing Neurological Applications 
      6.3.4 Cyclotron based production 
7. Market Segmentation By type of Radioisotopes 
Diagnostic Radioisotopes 
SPECT radioisotopes 
Technetium-99m (TC-99m) 
Thallium-201 (TL-201) 
Iodine (I-123) 
PET radioisotopes 
Rubidium-82 (RB-82) 
Therapeutic radioisotopes 
Alpha emitters 
Beta Emitters 
By geography 
North America Introduction US Canada Mexico 
7.4.2 Europe Introduction France UK Germany Italy Spain 
7.4.3 Asia-Pacific Introduction India China Japan Australia South Korea 
7.4.4 Middle-East and North Africa (MENA) Introduction GCC Egypt Algeria 
7.4.5 South America Introduction Brazil Argentina Others 
8. Competitive Landscape 
8.1 Mergers & Acquisitions 
8.2 New Product Launches 
8.3 Expansion 
8.4 Collaborations 
8.5 Market Share Analysis 
8.6 Price Value Analysis 
9. Company Profiles 
9.1 Covidien Plc 
9.2 GE Healthcare 
9.3 IBA Group 
9.4 Lantheus Medical Imaging, Inc. 
9.5 Nordion Inc. 
9.6 Siemens Healthcare 
10. Analyst Outlook for Investment Opportunities 
11. Future Outlook of the Market

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           


Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.